Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis

Jukka Rantanen; Thomas Rades; Clare Strachan

doi:10.1016/j.jpba.2023.115649

Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis

Jukka Rantanen^*, Thomas Rades, Clare Strachan

^*Corresponding author af dette arbejde

Publikation: Bidrag til tidsskrift › Review › peer review

5 Citationer (Scopus)

30 Downloads (Pure)

Abstract

The solid state of matter is the preferred starting point for designing a pharmaceutical product. This is driven by both patient preferences and the relative ease of supplying a solid pharmaceutical product with desired quality and performance. Solid form diversity is increasingly prevalent as a crucial element in designing these products, which underpins the importance of solid-state analytical methods. This paper provides a critical analysis of challenges related to solid-state analytics, as well as considerations and suggestions for feasible and meaningful pharmaceutical analysis.

Originalsprog	Engelsk
Artikelnummer	115649
Tidsskrift	Journal of Pharmaceutical and Biomedical Analysis
Vol/bind	236
Antal sider	7
ISSN	0731-7085
DOI	https://doi.org/10.1016/j.jpba.2023.115649
Status	Udgivet - 2023

Bibliografisk note

Funding Information:
This work has been supported by NordForsk (Oslo, Norway) - Nordic University Hub project Nordic POP (Patient Oriented Products; project number 85352 ).

Publisher Copyright:
© 2023 The Authors

Adgang til dokumentet

10.1016/j.jpba.2023.115649

FulltextForlagets udgivne version, 1,27 MBLicens: CC BY

Citationsformater

@article{8390c0587626476d9a048eae5da2aa57,

title = "Solid-state analysis for pharmaceuticals: Pathways to feasible and meaningful analysis",

abstract = "The solid state of matter is the preferred starting point for designing a pharmaceutical product. This is driven by both patient preferences and the relative ease of supplying a solid pharmaceutical product with desired quality and performance. Solid form diversity is increasingly prevalent as a crucial element in designing these products, which underpins the importance of solid-state analytical methods. This paper provides a critical analysis of challenges related to solid-state analytics, as well as considerations and suggestions for feasible and meaningful pharmaceutical analysis.",

keywords = "Analytical techniques, Dosage form, Process analytics, Product performance, Sample preparation, Solid-state properties",

author = "Jukka Rantanen and Thomas Rades and Clare Strachan",

note = "Funding Information: This work has been supported by NordForsk (Oslo, Norway) - Nordic University Hub project Nordic POP (Patient Oriented Products; project number 85352 ). Publisher Copyright: {\textcopyright} 2023 The Authors",

year = "2023",

doi = "10.1016/j.jpba.2023.115649",

language = "English",

volume = "236",

journal = "Journal of Pharmaceutical and Biomedical Analysis",

issn = "0731-7085",

publisher = "Elsevier",

}

TY - JOUR

T1 - Solid-state analysis for pharmaceuticals

T2 - Pathways to feasible and meaningful analysis

AU - Rantanen, Jukka

AU - Rades, Thomas

AU - Strachan, Clare

N1 - Funding Information: This work has been supported by NordForsk (Oslo, Norway) - Nordic University Hub project Nordic POP (Patient Oriented Products; project number 85352 ). Publisher Copyright: © 2023 The Authors

PY - 2023

Y1 - 2023

N2 - The solid state of matter is the preferred starting point for designing a pharmaceutical product. This is driven by both patient preferences and the relative ease of supplying a solid pharmaceutical product with desired quality and performance. Solid form diversity is increasingly prevalent as a crucial element in designing these products, which underpins the importance of solid-state analytical methods. This paper provides a critical analysis of challenges related to solid-state analytics, as well as considerations and suggestions for feasible and meaningful pharmaceutical analysis.

AB - The solid state of matter is the preferred starting point for designing a pharmaceutical product. This is driven by both patient preferences and the relative ease of supplying a solid pharmaceutical product with desired quality and performance. Solid form diversity is increasingly prevalent as a crucial element in designing these products, which underpins the importance of solid-state analytical methods. This paper provides a critical analysis of challenges related to solid-state analytics, as well as considerations and suggestions for feasible and meaningful pharmaceutical analysis.

KW - Analytical techniques

KW - Dosage form

KW - Process analytics

KW - Product performance

KW - Sample preparation

KW - Solid-state properties

U2 - 10.1016/j.jpba.2023.115649

DO - 10.1016/j.jpba.2023.115649

M3 - Review

C2 - 37657177

AN - SCOPUS:85168993780

SN - 0731-7085

VL - 236

JO - Journal of Pharmaceutical and Biomedical Analysis

JF - Journal of Pharmaceutical and Biomedical Analysis

M1 - 115649

ER -